A number of firms have modified their ratings and price targets on shares of GoodRx (NASDAQ: GDRX) recently:
- 8/20/2026 – GoodRx had its price target raised by Barclays PLC from $3.00 to $4.00. They now have an “underweight” rating on the stock.
- 8/15/2026 – GoodRx was upgraded by Wall Street Zen from “hold” to “buy”.
- 8/13/2026 – GoodRx had its price target raised by UBS Group AG from $2.50 to $3.75. They now have a “neutral” rating on the stock.
- 8/11/2026 – GoodRx had its price target raised by TD Cowen from $4.00 to $5.00. They now have a “buy” rating on the stock.
- 8/11/2026 – GoodRx had its price target raised by Citigroup Inc. from $4.00 to $5.00. They now have a “buy” rating on the stock.
- 8/7/2026 – GoodRx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
- 8/7/2026 – GoodRx had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $4.00 price target on the stock.
- 8/7/2026 – GoodRx had its price target raised by Wells Fargo & Company from $3.50 to $5.00. They now have an “overweight” rating on the stock.
- 8/6/2026 – GoodRx was given a new $5.00 price target by Leerink Partners.
- 7/23/2026 – GoodRx was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
- 7/23/2026 – GoodRx had its “buy” rating reaffirmed by Citigroup Inc..
- 7/8/2026 – GoodRx was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
Insider Activity
In related news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders have sold 2,760,995 shares of company stock valued at $9,673,207. 5.87% of the stock is currently owned by company insiders.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
See Also
- Five stocks we like better than GoodRx
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for GoodRx Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.
